GUSELKUMAB EFFICACY IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BY BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

被引：0
|
作者：
Deodhar, Atul [1 ]
Mease, Philip J. [2 ,3 ]
Boencke, Wolf-Henning [4 ]
Tesser, John [5 ]
Schiopu, Elena [6 ]
Chakravarty, Soumya D. [7 ,8 ]
Kollmeier, Alexa P. [9 ]
Hsia, Elizabeth C. [9 ,10 ]
Xu, Xie L. [9 ]
Shawi, May [11 ]
Jiang, Yusang [9 ]
Sheng, Shihong [9 ]
Agarwal, Prasheen [9 ]
Merola, Joseph F. [12 ]
McInnes, Iain B. [13 ]
Ritchlin, Christopher T. [14 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Geneva Univ Hosp, Geneva, Switzerland
[5] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA
[6] Michigan Med Rheumatol Clin, Ann Arbor, MI USA
[7] Janssen Sci Affairs LLC, Horsham, PA USA
[8] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
[9] Janssen Res & Dev LLC, Spring House, PA USA
[10] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[11] Janssen Global Serv LLC, Horsham, PA USA
[12] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[13] Univ Glasgow, Glasgow, Lanark, Scotland
[14] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2021年 / 27卷
关键词：
BIOLOGIC-NAIVE; DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PANLAR2021
引用
收藏
页码：S108 / S109
页数：2
相关论文
共 50 条
  • [41] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
    Mease, Philip J.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Chakravarty, Soumya D.
    Shawi, May
    Kollmeier, Alexa P.
    Xu, Xie L.
    Xu, Stephen
    Deodhar, Atul
    Baraliakos, Xenofon
    [J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1637 - 1653
  • [42] Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
    Gladman, Dafna D.
    Mease, Philip J.
    Bird, Paul
    Soriano, Enrique R.
    Chakravarty, Soumya D.
    Shawi, May
    Xu, Stephen
    Quinn, Sean T.
    Gong, Cinty
    Leibowitz, Evan
    Poddubnyy, Denis
    Tam, Lai-Shan
    Helliwell, Philip S.
    Kavanaugh, Arthur
    Deodhar, Atul
    Ostergaard, Mikkel
    Baraliakos, Xenofon
    [J]. TRIALS, 2022, 23 (01)
  • [43] Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
    Philip J. Mease
    Dafna D. Gladman
    Denis Poddubnyy
    Soumya D. Chakravarty
    May Shawi
    Alexa P. Kollmeier
    Xie L. Xu
    Stephen Xu
    Atul Deodhar
    Xenofon Baraliakos
    [J]. Rheumatology and Therapy, 2023, 10 : 1637 - 1653
  • [44] POOLED EFFICACY AND SAFETY FROM PHASE 3 PLACEBO-CONTROLLED STUDIES OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS
    Tive, L.
    Radin, D.
    Bello, A.
    Brown, M.
    West, C.
    Verburg, K.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2015, 23 : A355 - A355
  • [45] POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR
    Ritchlin, C. T.
    Rahman, P.
    Helliwell, P.
    Boehncke, W. H.
    Mcinnes, I.
    Gottlieb, A. B.
    Kafka, S.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Shawi, M.
    Sheng, S.
    Agarwal, P.
    Zhou, B.
    Ramachandran, P.
    Mease, P. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1300 - 1301
  • [46] Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
    Ritchlin, Christopher
    Rahman, Proton
    Helliwell, Philip
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice
    Kafka, Shelly
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Shawi, May
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Ramachandran, Paraneedharan
    Mease, Philip
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [47] GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS
    Nash, P.
    Tam, L. S.
    Tsai, W. C.
    Leung, Y. Y.
    Furtner, D.
    Sheng, S.
    Wang, Y.
    Shawi, M.
    Kollmeier, A.
    Sherlock, J.
    Cua, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 839 - 840
  • [48] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher T.
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya D.
    Rampakakis, Emmanouil
    Shawi, May
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB225 - AB225
  • [49] Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results fromphase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE
    Gottlieb, Alice B.
    Asahina, Akihiko
    Merola, Joseph F.
    McInnes, Iain
    Boehncke, Wolf-Henning
    Lebwohl, Mark
    Thaci, Diamant
    Ink, Barbara
    Coarse, Jason
    Warren, Richard B.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 97 - 98
  • [50] ACHIEVING STRINGENT CLINICAL DISEASE CONTROL CRITERIA IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE MEASURES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDIES
    Kristensen, L. E.
    Coates, L. C.
    Mease, P. J.
    Nash, P.
    Ogdie, A. R.
    Tillett, W.
    Gisondi, P.
    Ink, B.
    Prickett, A. R.
    Assudani, D.
    Bajracharya, R.
    Taieb, V
    Willems, D.
    Lambert, J.
    Walsh, J. A.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S413 - S413
12345